Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung Cancer

Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung Cancer

HeadHER1/EGFR is known to play a pivotal role in tumorigenesis and is overexpressed in up to 80% of NSCLCs. The study of an Expanded Access Clinical Program of Erlotinib in NSCLC is a phase IV openlabel, non-randomized, multicenter trial in patients with advanced (inoperable stage IIIb/IV) NSCLC who...

Full description

Bibliographic Details
Main Authors: Bakir Mehić, Mirko Stanetić, Ljuljeta Tinjić, Vlatka Smoljanović
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2008-11-01
Series:Bosnian Journal of Basic Medical Sciences
Subjects:
epidermal growth factor receptor
erlotinib
non small-cell lung cancer
Interim Data Report
TRUST study
Bosnia and Herzegovina
Online Access:http://www.bjbms.org/ojs/index.php/bjbms/article/view/2905

Similar Items

Similar Items